Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Adam C Mirando"'
Autor:
Natsuki Furukawa, Wendy Yang, Alex R. Chao, Akash Patil, Adam C. Mirando, Niranjan B. Pandey, Aleksander S. Popel
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract Chemokinostatin-1 (CKS1) is a 24-mer peptide originally discovered as an anti-angiogenic peptide derived from the CXCL1 chemokine. Here, we demonstrate that CKS1 acts not only as an anti-angiogenic peptide but also as an oncolytic peptide du
Externí odkaz:
https://doaj.org/article/535565cc213d4f06a93b1286166d686d
Autor:
Raquel Lima e Silva, Adam C. Mirando, Stephany Y. Tzeng, Jordan J. Green, Aleksander S. Popel, Niranjan B. Pandey, Peter A. Campochiaro
Publikováno v:
iScience, Vol 26, Iss 2, Pp 106078- (2023)
Summary: AXT107, a collagen-derived peptide that binds integrins αvβ3 and α5β1 with high affinity, suppresses vascular endothelial growth factor (VEGF) signaling, promotes angiopoietin 2-induced Tie2 activation, and suppresses neovascularization
Externí odkaz:
https://doaj.org/article/78fca1949d7a467b812527971c29c555
Autor:
Quan Dong Nguyen, Jeffrey S. Heier, Diana V. Do, Adam C. Mirando, Niranjan B. Pandey, Huan Sheng, Theresa Heah
Publikováno v:
International Journal of Retina and Vitreous, Vol 6, Iss 1, Pp 1-11 (2020)
Abstract Background Retinal vascular diseases such as neovascular age-related macular degeneration, diabetic retinopathy and/or diabetic macular edema, and retinal vein occlusion with macular edema—share several key pathophysiologic aspects includi
Externí odkaz:
https://doaj.org/article/c73aeaa6d0eb4d789f62f0374180f918
Autor:
Adam C. Mirando, Akash Patil, Christine I. Rafie, Brian J. Christmas, Niranjan B. Pandey, Vered Stearns, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Aleksander S. Popel
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved following
Externí odkaz:
https://doaj.org/article/d7ce52b28cfc47f195f57a6014ece82b
Autor:
Chen Zhao, Adam C Mirando, Richard J Sové, Thalyta X Medeiros, Brian H Annex, Aleksander S Popel
Publikováno v:
PLoS Computational Biology, Vol 15, Iss 11, p e1007468 (2019)
Macrophages respond to signals in the microenvironment by changing their functional phenotypes, a process known as polarization. Depending on the context, they acquire different patterns of transcriptional activation, cytokine expression and cellular
Externí odkaz:
https://doaj.org/article/5d56609b24fd4944b96a96ca96cfc190
Autor:
Raquel Lima e Silva, Adam C. Mirando, Elana Ben-Akiva, Ron B. Shmueli, Peter A. Campochiaro, Jordan J. Green, Niranjan B. Pandey, Jayoung Kim, Aleksander S. Popel, Stephany Y. Tzeng
Publikováno v:
Acta Biomater
Leading causes of vision loss include neovascular age-related macular degeneration (NVAMD) and macular edema (ME), which both require frequent intravitreal injections for treatment. A safe, poly(lactic-co-glycolic acid) (PLGA)-based biodegradable pol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89cdc0b6b73edb8ff156d88f48ce4e33
https://doi.org/10.1016/j.actbio.2019.07.054
https://doi.org/10.1016/j.actbio.2019.07.054
Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma
Autor:
Yu Zhang, Phuoc T. Tran, Aleksander S. Popel, Richard J. Sové, Ludmila Danilova, Elana J. Fertig, Mark Yarchoan, Adam C. Mirando, Mohammad Jafarnejad, Niranjan B. Pandey
Publikováno v:
npj Systems Biology and Applications, Vol 5, Iss 1, Pp 1-14 (2019)
NPJ Systems Biology and Applications
NPJ Systems Biology and Applications
Hepatocyte growth factor (HGF) signaling through its receptor Met has been implicated in hepatocellular carcinoma tumorigenesis and progression. Met interaction with integrins is shown to modulate the downstream signaling to Akt and ERK (extracellula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13572fa3761f96ec2bcb14d8fb63ca6
http://link.springer.com/article/10.1038/s41540-019-0107-2
http://link.springer.com/article/10.1038/s41540-019-0107-2
Autor:
Phuoc T. Tran, Adam C. Mirando, Jordan J. Green, Niranjan B. Pandey, Ghali Lemtiri-Chlieh, Mustafa A. Barbhuiya, Brian W. Simons, Aleksander S. Popel
Publikováno v:
Oncotarget
// Mustafa A. Barbhuiya 1, * , Adam C. Mirando 2, * , Brian W. Simons 3 , Ghali Lemtiri-Chlieh 1 , Jordan J. Green 2 , Aleksander S. Popel 2 , Niranjan B. Pandey 2 and Phuoc T. Tran 1, 3 1 Department of Radiation Oncology and Molecular and Radiation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7bb14d5601de2ff77827b7395e0f588
https://doi.org/10.18632/oncotarget.21148
https://doi.org/10.18632/oncotarget.21148
Autor:
Niranjan B. Pandey, Adam C. Mirando, Jeffrey S. Heier, Diana V. Do, Theresa Heah, Quan Dong Nguyen, Huan Sheng
Publikováno v:
International Journal of Retina and Vitreous
International Journal of Retina and Vitreous, Vol 6, Iss 1, Pp 1-11 (2020)
International Journal of Retina and Vitreous, Vol 6, Iss 1, Pp 1-11 (2020)
Background Retinal vascular diseases such as neovascular age-related macular degeneration, diabetic retinopathy and/or diabetic macular edema, and retinal vein occlusion with macular edema—share several key pathophysiologic aspects including neovas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a81cb8dc8c288d4f218928518c8b2252
http://europepmc.org/articles/PMC7557096
http://europepmc.org/articles/PMC7557096
Autor:
Vered Stearns, Evanthia T. Roussos Torres, Aleksander S. Popel, Brian J. Christmas, Christine I. Rafie, Elizabeth M. Jaffee, Akash Patil, Niranjan B. Pandey, Adam C. Mirando
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22f06116de0c50e9c19dc84a05ff3a51
https://pubmed.ncbi.nlm.nih.gov/32923118
https://pubmed.ncbi.nlm.nih.gov/32923118